Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 4/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31352975 | 0.83 | MTNR1B (0.56) | NFE2L2KEAP1FFAR4PGRCA12 | |
| SCHEMBL3151230 | 0.83 | MTNR1B (0.56) | NFE2L2KEAP1FFAR4PGRCA12 | |
| SCHEMBL29650302 | 0.82 | NFE2L2 (0.54) | NFE2L2KEAP1FFAR4PGRTAS2R14 | |
| SCHEMBL803706 | 0.82 | NFE2L2 (0.54) | NFE2L2KEAP1FFAR4PGRTAS2R14 | |
| SCHEMBL11155550 | 0.82 | NFE2L2 (0.54) | NFE2L2KEAP1FFAR4PGRTAS2R14 | |
| SCHEMBL29782844 | 0.81 | PGR (0.61) | NFE2L2KEAP1FFAR4PGRTAS2R14 | |
| SCHEMBL4952964 | 0.81 | PGR (0.61) | NFE2L2KEAP1FFAR4PGRTAS2R14 | |
| SCHEMBL13290766 | 0.80 | NFE2L2 (0.53) | NFE2L2KEAP1FFAR4PGRTAS2R14 | |
| SCHEMBL18152 | 0.80 | NFE2L2 (0.53) | NFE2L2KEAP1FFAR4PGRTAS2R14 | |
| SCHEMBL2377950 | 0.80 | NFE2L2 (0.53) | NFE2L2KEAP1FFAR4PGRTAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119219808-A | Multifunctional ionic polymer, preparation method and application thereof, and ion exchange membrane | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED | 2008-12-25 | — | — | US | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1814873-A2 | 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-08-08 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006038006-A2 | 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | HTR6, HTR5A, TPH1 | NFE2L2 3671/4885KEAP1 2343/4885FFAR4 186/4885 |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | NFE2L2 3293/4885KEAP1 1841/4885FFAR4 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.